Market Cap. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. : 001-35203 Mr. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. Senior Director, Investor Relations. Learn why it. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. - Cash, bonds and money market funds of US$22. Theratechnologies Stock Price, News and Company Updates. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. Elif McDonald - Senior Director, Investor Relations. 35 as of 10:41 a. NCU. By continuing to use our service, you agree to our use of cookies. - Issued and outstanding common shares to be consolidated on the basis of 1 post. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. For investor inquiries: Leah Gibson. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. The FDA granted fast track designation to TH1902 as a single agent for. By continuing to use our service, you agree to our use of cookies. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. First Quarter Fiscal 2022 Financial Results. This suggests a possible upside of 2,471. MONTREAL, Feb. . (TH. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. - October 10, 2023) - KO Gold Inc. com uses cookies on this site. Stockhouse. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. Shares of Theratechnologies are up 4. THERATECHNOLOGIES INC. TH | March 7, 2023. The abstracts are now available at aacr. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. com uses cookies on this site. Losses were -47. 4% from the stock's current price. T. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. 60%. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. Revenues have been growing at an average rate of 10. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. com uses cookies on this site. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. Theratechnologies inc. This news release constitutes a “designated news release” for the purposes of the. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. This news release constitutes a “designated news release” for the purposes of the Company’s. GlobeNewswire. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. The company reported ($0. 71. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. European Headquarters. Investor inquiries: Elif McDonald. By continuing to use our service, you agree to our use of cookies. Contact Email communications@theratech. . View Company Info for Free. 65 per cent to C$1. Montréal, Québec, Canada . Montréal, Québec, Canada . 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. . T. On average, they expect the company's stock price to reach $36. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. THERATECHNOLOGIES INC. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH1902 combines Theratechnologies’ proprietary peptide to. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. e. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. 67, which is an increase of 1,144. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. stock news by MarketWatch. T. Stockhouse. - Q3 2022 Consolidated. . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. 2. 67% from the latest price. Theratechnologies. TO) on CEO. Company Description: Theratechnologies is pepped up on peptides. By continuing to use our service, you agree to our use of cookies. 82 million. m. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Shares of Theratechnologies are up 4. Headquarters. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. 5%. FAQ – Utilisateurs de TMX Argent NOUVEAU. Theratechnologies, Inc. com uses cookies on this site. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Vice President, Communications and Corporate Affairs. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Christian Marsolais, Ph. View real-time stock prices and stock quotes for a full financial overview. Further. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. We currently market prescription products for people with HIV in the United States. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. -based clinical sites participating in the conduct of the Phase. MONTREAL, Nov. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. Headquarters. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. com. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. MONTREAL, Aug. stock news by MarketWatch. com uses cookies on this site. Stockhouse. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. By continuing to use our service, you agree to our use of cookies. 8 and 1. Cookies are used to offer you a better browsing experience and to analyze our traffic. Company Type For Profit. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. During the last trading day the stock fluctuated 12. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (882) posted 3 minutes ago. Track Theratechnologies Inc. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. Investor Relations. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. [email protected] Inc: Overview. Competitors: Unknown. By continuing to use our service, you agree to our use of cookies. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. About Us | Theratechnologies Inc. 51 to 200 Employees. By continuing to use our service, you agree to our use of cookies. H. . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. com. . MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our. By continuing to use our service, you agree to our use of cookies. Data presented at AMCP Nexus 2023. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Marsolais will present at the H. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. Theratechnologies Inc. Theratechnologies inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. TH | October 13, 2022 - Q3 2022 Consolidated. (“Theratechnologies”) with the Securities and Exchange Commission (the. Stockhouse. If you have HIV, it's important to know the difference. com. US Headquarters. com uses cookies on this site. Rosenberg, Reference is made to your letter dated August 16, 2012 regarding the Form 40-F for fiscal year-end November 30, 2011 filed by Theratechnologies Inc. com. Theratechnologies Inc. VANCOUVER, British Columbia, Nov. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. home message. -986. By continuing to use our service, you agree to our use of cookies. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. FY2023 revenue guidance range set between $90 million and $95 million. 5000 0. La Bourse de Toronto a clôturé en hausse mardi pour une troisième séance consécutive, tandis que les grands indices boursiers américains ont avancé eux aussi. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. We also use them to share usage. GUD | Complete Knight Therapeutics Inc. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. In 2022, THTX's revenue was 80. Cookies are used to offer you a better browsing experience and to analyze our traffic. 75%. Non-Profit & Charitable Organizations · United States · <25 Employees. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. MONTREAL, Sept. TH | July 20, 2023. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. MONTREAL, Aug. Further. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. The financial results presented in this press release are taken from the. Q4 2022 consolidated revenue growth of 14. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. communications@theratech. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. . Find the latest Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. US Headquarters. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to. 9 million and US. com uses cookies on this site. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. MONTREAL, Nov. By continuing to use our service, you agree to our use of cookies. TH | July 20, 2023. 4 million. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. Investor inquiries: Elif McDonald. Theratechnologies . Stockhouse. 39 50-Day Range $0. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. MONTREAL, Sept. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. Stockhouse. Theratechnologies is pepped up on peptides. Consensus forecasts updated Jul 21. Agreement in principle on key amendments to loan. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. com uses cookies on this site. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Sept. : Nasdaq Theratechnologies Inc. MONTREAL, Feb. Stockhouse. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. Follow. com uses cookies on this site. 86 million for the quarter. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. THTX | Complete Theratechnologies Inc. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. . m. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. OTCQX – this is the premium tier of OTC stocks. com. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. View real-time stock prices and stock quotes for a full financial overview. com uses cookies on this site. 57%) Q1 2020 Earnings Call. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. Stockhouse. Denis Boucher. MONTREAL, Oct. TH 48% v4,15M c1. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TH. Theratechnologies inc. Remember, high Theratechnologies' alpha is almost always a sign of. Theratechnologies Announces 1-for-4 Reverse Stock Split. “This is yet another major achievement for our oncology program. 514-336-7800. com uses cookies on this site. 54% and a negative trailing twelve-month return on equity of 1,116. Stockhouse. Cookies are used to offer you a better browsing experience and to. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. FAQ – Émetteurs inscrits NOUVEAU. Apr 14, 2020, 8:30 a. By continuing to use our service, you agree to our use of cookies. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. One reason for that is that this tier does not include penny stocks. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. (Image via Theralase Technologies Inc. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 23) earnings per share over the last year ( ($1. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. " The 12-month stock price forecast is $18. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. View real-time stock prices and stock quotes for a full financial overview. By continuing to use our service, you agree to our use of cookies. (THTX) NasdaqCM - NasdaqCM Real Time Price. The money will be used to grow the company’s FDA-approved drugs, Egrifta SV (tesamorelin), used for the reduction of excess. Theratechnologies Inc. GUD | Complete Knight Therapeutics Inc. We also use them to share usage. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. By continuing to use our service, you agree to our use of cookies. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Stockhouse. 4%. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . 1M. ("Theratechnologies" or the "Company"). MONTREAL, Feb. T. lgibson. S. By continuing to use our service, you agree to our use of cookies. We also use them to share usage information with our partners. 23 to a day high of $1. Montreal-based biopharmaceutical company Theratechnologies Inc. Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Globe Newswire - Wed Nov 3, 2021 . (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. MONTREAL, Oct. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in people with HIV. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. TH | February 28, 2023. Stockhouse. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category.